ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $1.82B

      Shares

      4.68M

      % of Portfolio

      8.01%

      Average Buy Price

      $128

      Avg closing price
      Price range

      50 Terry Smith Stryker Trades

      Terry Smith's position in Stryker is currently worth $1.82B. That's 8.01% of their entire equity portfolio (3rd largest holding). The investor owns 1.21% of the outstanding Stryker stock. The first Stryker trade was made in Q1 2013. Since then Terry Smith bought shares 35 more times and sold shares on fourteen occasions. The stake costed the investor $599M, netting the investor a gain of 204% so far.

      Avg closing price
      Price range
      Sold 7.7% shares (-392k shares) Q2 2025
      Avg closing price $373.74
      Price range $337.37 - $395.63
      Sold 5.0% shares (-265k shares) Q1 2025
      Avg closing price $380.39
      Price range $355.32 - $399.92
      Sold 0.1% shares (-2.84k shares) Q4 2024
      Avg closing price $370.80
      Price range $345.14 - $392.15
      Sold 0.4% shares (-19.4k shares) Q3 2024
      Avg closing price $345.19
      Price range $315.94 - $371.96
      Sold 2.2% shares (-123k shares) Q2 2024
      Avg closing price $338.73
      Price range $324.30 - $354.67
      Sold 0.6% shares (-33.6k shares) Q1 2024
      Avg closing price $336.44
      Price range $293.94 - $358.71
      Sold 0.1% shares (-6.18k shares) Q4 2023
      Avg closing price $280.67
      Price range $253.85 - $299.46
      Increased shares by 0.1% (+7.16k shares) Q3 2023
      Avg closing price $286.76
      Price range $266.54 - $302.43
      Increased shares by 0.2% (+13.3k shares) Q2 2023
      Avg closing price $288.84
      Price range $271.49 - $305.09
      Sold 1.9% shares (-109k shares) Q1 2023
      Avg closing price $265.32
      Price range $246.03 - $285.47
      Sold 0.4% shares (-21.5k shares) Q4 2022
      Avg closing price $226.93
      Price range $205.51 - $253.95
      Sold 7.0% shares (-421k shares) Q3 2022
      Avg closing price $210.35
      Price range $189.27 - $231.83
      Increased shares by 3.5% (+204k shares) Q2 2022
      Avg closing price $234.88
      Price range $194.09 - $276.37
      Sold 19.4% shares (-1.41M shares) Q1 2022
      Avg closing price $258.78
      Price range $245.33 - $277.77
      Increased shares by 3.4% (+237k shares) Q4 2021
      Avg closing price $262.45
      Price range $236.63 - $276.44
      Increased shares by 0.0% (+1.37k shares) Q3 2021
      Avg closing price $267.36
      Price range $248.90 - $280.09
      Increased shares by 0.1% (+7.64k shares) Q2 2021
      Avg closing price $255.73
      Price range $242.95 - $267.00
      Increased shares by 5.6% (+372k shares) Q1 2021
      Avg closing price $239.81
      Price range $221.01 - $248.82
      Increased shares by 5.7% (+358k shares) Q4 2020
      Avg closing price $226.50
      Price range $202.01 - $245.04
      Increased shares by 1.2% (+72.6k shares) Q3 2020
      Avg closing price $194.38
      Price range $177.77 - $215.81

      News about Stryker Corp. and Terry Smith

      Tracking Terry Smith''s Fundsmith 13F Portfolio - Q1 2024 Update

      Tracking Terry Smith''s Fundsmith 13F Portfolio - Q1 2024 Update

      Fundsmith''s 13F portfolio value rises to $25.55B, with top holdings in Microsoft, Meta Platforms, and Stryker Corp. Read a portfolio update here.

      Seeking Alpha Seeking Alpha, over 1 year ago
      Inside information: Alan Donze has been appointed as Bioretec's new CEO

      Inside information: Alan Donze has been appointed as Bioretec's new CEO

      Bioretec Ltd Inside information 20 May 2024 at 6:00 p.m. EEST TAMPERE, Finland, May 20, 2024 /PRNewswire/ -- Bioretec Ltd is pleased to announce that Mr. Ala...

      https://www.prnewswire.com https://www.prnewswire.com, over 1 year ago
      Inside information: Alan Donze has been appointed as Bioretec's new CEO

      Inside information: Alan Donze has been appointed as Bioretec's new CEO

      Bioretec Ltd Inside information 20 May 2024 at 6:00 p.m. EEST TAMPERE, Finland, May 20, 2024 /PRNewswire/ -- Bioretec Ltd is pleased to announce that Mr. Ala...

      https://www.prnewswire.com https://www.prnewswire.com, over 1 year ago
      SYK Stock Earnings: Stryker Beats EPS, Beats Revenue for Q1 2024

      SYK Stock Earnings: Stryker Beats EPS, Beats Revenue for Q1 2024

      Stryker (NYSE: SYK ) just reported results for the first quarter of 2024. Stryker reported earnings per share of $2.50. This was above the analyst estimate f...

      InvestorPlace InvestorPlace, over 1 year ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×